欢迎来到360期刊网!
学术期刊
  • 学术期刊
  • 文献
  • 百科
电话
您当前的位置:

首页 > 学术期刊 > 癌症生物学与医学(英文版)杂志

癌症生物学与医学(英文版)

癌症生物学与医学(英文版)杂志

Cancer Biology & Medicine 림상종류여암증구(영문판)

  • 主管单位: 中国科学技术协会
  • 主办单位: 中国抗癌协会
  • 影响因子: 1.07
  • 审稿时间:
  • 国际刊号: 2095-3941
  • 国内刊号: 12-1431/R
  • 发行周期:
  • 邮发: 6-173
  • 曾用名: 中国肿瘤临床(英文版);癌症生物学与医学(英文版);临床肿瘤与癌症研究(英文版)
  • 创刊时间: 2004
  • 语言: 英文
  • 编辑单位: Cancer Biology & Medicine 编辑部
  • 出版地区:
  • 主编: 郝希山
  • 类 别:
期刊收录:
期刊荣誉:
  • 作者:

    hTere are notable differences in the incidence and mortality rates for prostate cancer between Asia and Western countries. It is also recognized that there are differences in thinking with regard to treatment options. Recently it is also the case that opinions have been reported concerning the differences between Asian and Western patients with regard to their reaction to androgen depletion therapy (ADT). Given that ADT is a method of treatment that focuses on the elimination of testosterone, an inevitable symptom of its administration is testosterone losing syndrome. It is for this reason that in Western countries ADT has only been recommended in cases of advanced or metastatic cancer. On the other hand, in Asia, ADT is used in relatively many cases, including non-metastatic localized cancer and invasive localized cancer. To date, however, there has been little substantive discussion concerning this difference in utilization of ADT. ADT-related drugs for prostate cancer and the development of new drugs for castration resistant prostate cancer (CRPC) have been actively tested in recent years. It could be the case that analyzing the differences in concepts about ADT between Asia and the West could contribute to the effective use of ADT-related drugs and also help to build new treatment strategies for prostate cancer.

  • 作者:

    Eat more‘green’ or eat‘ifve a day’ is one of the most important healthy lifestyle behaviours in the 21 century. Aiming to ifght cancer effectively, more than half patients use vitamins or herbs concurrently with conventional anticancer treatment. Flavonoids or polyphenols existing in vegetables, fruits and green tea are common plant pigments with antioxidant properties and considered acting as cancer preventing or anti-cancer agents. Recently it was found that some lfavonoids and vitamin C in diet or supplements have antagonistic effect with the anti-cancer drug bortezomib. Bortezomib is a speciifc inhibitor for proteasome and is currently used for treatment of relapsed and refractory multiple myeloma. Despite its successful rates in treating multiple myeloma and other solid tumors, it is unable to kill leukemic cells in the blood. It was recently revealed that some lfavonoids and vitamin C present in green leaves and green teas in the blood can neutralize bortezomib by directly interaction between two chemicals. Here we summarize why dietary lfavonoids should be avoided in patients who take bortezomib as chemotherapeutic drug.

  • 作者:

    Receptor tyrosine kinases (RTKs) such as the epidermal growth factor receptor (EGFR) regulate cellular homeostatic processes. EGFR activates downstream signaling cascades that promote tumor cell survival, proliferation and migration. Dysregulation of EGFR signaling as a consequence of overexpression, amplification and mutation of the EGFR gene occurs frequently in several types of cancers and many become dependent on EGFR signaling to maintain their malignant phenotypes. Consequently, concerted efforts have been mounted to develop therapeutic agents and strategies to effectively inhibit EGFR. However, limited therapeutic beneifts to cancer patients have been derived from EGFR-targeted therapies. A well-documented obstacle to improved patient survival is the presence of EGFR-inhibitor resistant tumor cell variants within heterogeneous tumor cell masses. Here, we summarize the mechanisms by which tumors resist EGFR-targeted therapies and highlight the emerging role of microRNAs (miRs) as downstream effector molecules utilized by EGFR to promote tumor initiation, progression and that play a role in resistance to EGFR inhibitors. We also examine evidence supporting the utility of miRs as predictors of response to targeted therapies and novel therapeutic agents to circumvent EGFR-inhibitor resistance mechanisms.

  • 作者:

    Cancer genomics is a rapidly growing discipline in which the genetic molecular basis of malignancy is studied at the scale of whole genomes. While the discipline has been successful with respect to identifying specific oncogenes and tumor suppressors involved in oncogenesis, it is also challenging our approach to managing patients suffering from this deadly disease. Speciifcally cancer genomics is driving clinical oncology to take a more molecular approach to diagnosis, prognostication, and treatment selection. We review here recent work undertaken in cancer genomics with an emphasis on translation of genomic ifndings. Finally, we discuss scientiifc challenges and research opportunities emerging from ifndings derived through analysis of tumors with high-depth sequencing.

  • 作者:

    Objective:To study explores the effect of HLEC on the secreted proteins of epithelial ovarian cancer (EOC) cells (SKOV3-PM4) with directional highly lymphatic metastasis.
    Methods:Supernatants of four groups of cultured cells, namely, SKOV3 (A), SKOV3+HLEC (B), SKOV3-PM4 (C), SKOV3-PM4+HLEC (D), were collected, and their proteins were detected by antibody arrays and iTARQ-2D-LC-MALDI-TOF/TOF/MS. Signiifcantly differential proteins were further analyzed via bioinformatics and validated in human serums and cell media via ELISA.
    Results:Results of antibody arrays and mass spectrometry demonstrated that GRN and VEGFA were upregulated in group C (compared with group A), whereas IGFBP7 and SPARC were downregulated in group D (compared with group C). Comprehensive bioinformatics analysis results showed that IGFBP7 and VEGFA were closely linked to each other. Further validation with serums showed statistical signiifcance in VEGFA and IGFBP7 levels among groups of patients with ovarian cancers, benign tumors, and control groups. Two proteins were upegulated in the ifrst group. VEGFA in the control group was downregulated. For IGFBP, upregulation in the control group and down-regulation in the ifrst group were also observed.
    Conclusion:The HLEC microenvironment is closely associated with directional metastasis to lymph nodes and with differential proteins including cell stromal proteins and adhesion factors. hTe upregulation of VEGFA and GRN and the downregulation of SPARC and IGFBP7 are closely associated with directional metastasis to lymph nodes in EOC cells.

  • 作者:

    Objective:To investigate the recurrence sites, risk factors, and prognosis of patients with persistent or recurrent squamous cell carcinoma (SCC) of the cervix within one year atfer undergoing concurrent chemoradiotherapy (CCRT).
    Methods:Clinical data of 30 patients with persistent or recurrent SCC of the cervix within one year atfer CCRT between July 2006 and July 2011 were analyzed retrospectively. hTese data were compared with those of 35 SCC cases with no signs of recurrence atfer complete remission. hTese 35 patients were treated during the same period (between 2006 and 2011) and selected randomly.
    Results:Among these 30 patients, 25 exhibited distant metastases of which 14 were observed within 6 months atfer CCRT. Univariate analysis showed higher incidence of pelvic or para-aortic lymphadenectasis and SCC-ag>10 ng/mL in the group with persistent or recurrent disease before treatment (P<0.01). Multivariate analysis by logistic regression revealed that the pre-therapeutic pelvic or para-aortic lymph node enlargement and SCC-ag>10 ng/mL were the independent risk factors. Palliative chemotherapy was the main treatment option for patients with persistent or recurrent disease. hTe 2-year survival rate was 21.7%, and the median survival time was 17 months.
    Conclusion:Patients with persistent or recurrent SCC of the cervix atfer CCRT exhibited a high rate of distant metastasis with poor prognosis. The pre-therapeutic pelvic or para-aortic lymph node enlargement and SCC-ag>10 ng/mL were identiifed as the independent risk factors for persistent or recurrent SCC within 1 year atfer CCRT.

  • 作者:

    关键词:
  • 作者:

    Myeloid sarcoma (MS) is a rare hematological neoplasm that develops either de novo or concurrently with acute myeloid leukemia (AML). This neoplasm can also be an initial manifestation of relapse in a previously treated AML that is in remission. A 44-year-old male patient was diagnosed with testis MS in a local hospital in August 2010. Atfer one month, bone marrow biopsy and aspiration conifrmed the diagnosis of AML. Allogeneic mobilization peripheral blood stem cell transplantation was performed, with the sister of the patient as donor, after complete remission (CR) was achieved by chemotherapy. Five months after treatment, an adrenal mass was detected by positron emission tomography-computed tomography (PET-CT). Radiotherapy was performed for the localized mass after a multidisciplinary team (MDT) discussion. hTe patient is still alive as of May 2013, with no evidence of recurrent MS or leukemia.

  • 作者:

    The last ten years have seen remarkable progress in cancer research. However, despite significant breakthroughs in the understanding, prevention, and treatment of cancer, the disease continues to affect millions of people worldwide. Cancer’s complexity compounded with ifnancial, policy and regulatory roadblocks has slowed the rate of progress being made against cancer. In this paper, we review a few of the most recent breakthroughs that are fueling medical advances and bringing new hope for patients affected by this devastating disease. We also address the challenges facing us and the opportunities to accelerate future progress against cancer. The efforts of the American Association for Cancer Research (AACR) to address the cancer burden already extend beyond the borders of the United States of America. hTe AACR is committed to increasing its efforts to stem the tide of cancer worldwide by promoting innovative programs, strategies, and initiatives for cancer researchers and all those engaged in cancer-related biomedical sciences around the world.

癌症生物学与医学(英文版)分期目录
期数
2018 01 03 z1
2017 01 02 03 04
2016 01 02 03 04
2015 01 02 03 04
2014 01 02 03 04
2013 01 02 03 04
2012 01 02 03 04
2011 01 02 03 04
2010 01 02 03 04 05 06
2009 01 02 03 04 05 06
2008 01 02 03 04 05 06
2007 01 02 03 04 05 06
2006 01 02 03 04 05 06
2005 01 02 03 04 05 06

360期刊网

专注医学期刊服务15年

  • 您好:请问您咨询什么等级的期刊?专注医学类期刊发表15年口碑企业,为您提供以下服务:

  • 1.医学核心期刊发表-全流程服务
    2.医学SCI期刊-全流程服务
    3.论文投稿服务-快速报价
    4.期刊推荐直至录用,不成功不收费

  • 客服正在输入...

x
立即咨询